SPOTLIGHT -
Amitkumar Mehta, MD, on Compelling Data From ASH in the Treatment of Lymphoma
Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.
Amitkumar Mehta, MD, on Results of CITADEL-205 Study Examining Parsaclisib in Relapsed/Refractory MCL
Amitkumar Mehta, MD, discusses overall response rates from the CITADEL-205 study looking at parsaclisib for patients with relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta, MD, Discusses the Role of Parsaclisib in Relapsed/Refractory MCL
Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta on the Immunomodulating Effects of Targeted Therapy for Multiple Myeloma
In this interview we discuss the mechanisms of daratumumab, how it is currently used for the treatment of multiple myeloma, and how it might be used in the future.
